The Fund aims to achieve a long-term return, in excess of the long-term return that is typically achieved from US Smaller companies equity markets ('“the US'”).
Name | % Net Assets |
---|---|
Phillips-Van Heusen | 2.3% |
Tellabs | 2.3% |
Omniture | 2.2% |
Inverness Medical Innovations | 2.0% |
Solera | 2.0% |
Reinsurance Group America | 2.0% |
Bank of The Ozarks | 1.9% |
Western Alliance Bancorp | 1.9% |
Hanover Insurance Group | 1.8% |
Pactiv | 1.8% |
Key | % Net Assets |
---|---|
Phillips-Van Heusen | 2.3% |
Tellabs | 2.3% |
Omniture | 2.2% |
Inverness Medical Innovations | 2.0% |
Other | 91.2% |
Date | 14-Aug-2009 |
---|---|
NAV | 265.63p |
Currency | GBP |
Change | 4.16p |
% | 1.59% |
YTD change | 265.63p |
YTD % | n/a |
Fund Inception | 01/02/1990 |
---|---|
Fund Manager | Chuck Purcell / Bill Gerlach |
TER | - |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | -0.03 |
You are here: research